Setting out an ambitious strategy
and ensuring that it is implemented
The corporate governance of BIOASTER consists of a Board of Directors and a Scientific Advisory Board.
Philippe Archinard – President
Board of directors
UNIVERSITÉ DE LYON
Guy-Charles Fanneau de La Horie
Recteur de la région académique Auvergne-Rhône-Alpes, Chancelier des universités
LE MONDE VÉTÉRINAIRE
LA METROPOLE DE LYON
RÉGION AUVERGNE RHÔNE-ALPES
CEO, PharmD, MBA
In parallel with his work, he co-founded SPI-Bio in 1991. After completing training in business management, he took over the general management of the company in 1996. He was confirmed in this role when the company joined Bertin Technologies in 2004. Within the group, Xavier was the architect of the development of the company, which combined organic growth and strategic acquisitions, leading to the creation of Bertin Pharma in 2010.
When the company had grown to have a workforce of around fifty, Xavier joined Oncodesign when it acquired Bertin. He then led the business development and marketing activities of Oncodesign. He was very active in the R&D ecosystem, participating in the creation of Afssi, of which he became President. He is also a Member of the Academy of Pharmacy.
Deputy CEO Administration and Public Affairs
Chief Scientific Officer, PhD
- Deputy CSO & Director of Technologies, BIOASTER, Lyon
- Principal Investigator and Molecular Microbiologist, Respiratory Infections, Public Health, Toronto, Ontario, Canada.
- Assistant Professor in Medicine, Faculty of Department of Laboratory Medicine and Pathobiology, University of Toronto.
- Scientist, Mount Sinai Hospital, Toronto, Ontario, Canada.